The field of cardiovascular disease is increasingly focused on understanding the interconnected yet distinct nature of aortic valve disease—especially ...
The EuroPCR Course Directors have selected 3 major late-breaking trials that will be presented for the first time during EuroPCR 2026 and are set to impact practice worldwide.
Reflow Medical announced the first six-month clinical results from a study of its Spur Elute sirolimus-eluting retrievable ...
An aortic aneurysm grows in silence, shows no symptoms, and kills within minutes when it ruptures. A Hyderabad vascular surgeon is calling for greater public awareness of a condition that remains ...
Artivion has finalized its acquisition of Endospan Ltd., adding the FDA-approved NEXUS Aortic Arch System to its portfolio of ...
Learn how aneurysms develop, what symptoms to watch for, and how medical professionals treat weakened artery walls.
Boston Scientific Corporation BSX said it invested $1.5 billion in privately held MiRus, securing an approximately 34% equity ...
As per a 2019 deal, Artivion secured the rights to purchase Endospan upon the latter’s US approval of Nexus, a treatment for ...
Endospan Announces Closing of Acquisition by Artivion, Inc., Following FDA PMA Approval of the NEXUS® Aortic Arch SystemThe Associated PressHERZLIYA, Israel HERZLIYA, Israel–(BUSINESS WIRE)–May 18, ...
ATLANTA, May 18, 2026 Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it has completed ...
(NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it has completed the acquisition of its long-standing partner Endospan Ltd. ("Endospan"), a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results